The authors wish to make corrections to the authorship and title of [1]. The corrected authorship is as follows: Julia Chisholm and Henry Mandeville contributed equally to the first authorship. Johannes H. M. Merks and Meriel Jenney contributed equally to senior authorship. In the title FAR-RMS has been corrected to FaR-RMS.
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Chisholm, J.; Mandeville, H.; Adams, M.; Minard-Collin, V.; Rogers, T.; Kelsey, A.; Shipley, J.; van Rijn, R.R.; de Vries, I.; van Ewijk, R.; et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancers 2024, 16, 998. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).